Airfinity shortlisted at the Reuters Pharma Awards 2022

Posted on Sep 12, 2022

Airfinity has been shortlisted for Most Valuable Data & Insights Initiative at the Reuters Pharma Awards 2022 for its work supporting governments and pharma in the global response to COVID-19.

It is an honour to be recognised alongside fellow finalists AstraZeneca, Novartis, and ATMPS.

View the full list of shortlisted companies here.

To request more information about our work in COVID-19 and infectious diseases, get in touch here.

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022